Sarepta Therapeutics, Inc. (SRPT) - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on rare diseases, primarily Duchenne muscular dystrophy (DMD). The company's portfolio includes PMO products (EXONDYS 51, VYONDYS 53, AMONDYS 45) and the gene therapy ELEVIDYS. The reporting period reflects the aftermath of a strategic restructuring announced in July 2025, a change in CEO leadership (Michael Severino appointed July 2026), and ongoing regulatory challenges regarding ELEVIDYS safety and the ESSENCE confirmatory trial results for PMO products.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $401.3 million | $611.1 million | $1,132.1 million | $1,355.9 million |
| Net (Loss) Income | $(4.9) million | $196.9 million | $326.1 million | $(250.6) million |
| Operating Income (Loss) | $13.3 million | $115.6 million | $371.7 million | $(184.8) million |
| Diluted EPS | $(0.05) | $1.89 | $2.99 | $(2.57) |
| Cash & Investments | $945.0 million (as of June 30, 2026) | |||
| Long-Term Debt | $847.6 million (as of June 30, 2026) |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 34% in Q2 2026 compared to Q2 2025. This was driven primarily by a 65% drop in ELEVIDYS product revenue ($98.1M vs. $281.9M) due to the suspension of shipments to non-ambulatory patients and a label update restricting use to ambulatory patients following safety events. PMO product revenue remained relatively flat.
- Collaboration Revenue Spike (YTD): Collaboration and other revenue increased 104% year-over-year for the six-month period to $472.9 million. This was largely due to a $325.0 million revenue recognition event when Roche declined to exercise an option for certain program rights, and a $40.0 million milestone for the first commercial dosing of ELEVIDYS in Japan.
- Expense Reduction: Research and Development (R&D) expenses decreased 55% in Q2 2026 ($91.3M vs. $204.4M) and 75% YTD. This significant reduction is attributed to the July 2025 restructuring, workforce reductions, and the absence of the $583.6 million up-front license fee paid to Arrowhead in the prior year.
- Profitability Shift: The company reported a net loss of $4.9 million in Q2 2026, contrasting with a net income of $196.9 million in Q2 2025. However, on a YTD basis, the company returned to profitability with $326.1 million in net income, compared to a loss of $250.6 million in the prior year.
- Litigation Charge: A one-time litigation contingency charge of $39.0 million was recorded in Q2 2026 related to the potential resolution of certain patent litigations.
Guidance, Outlook, and Risks
- ELEVIDYS Status: Shipments to ambulatory patients resumed in July 2025. However, the non-ambulatory population was removed from the label in November 2025 due to a boxed warning for acute liver injury/failure. The company is conducting a study with sirolimus to evaluate a pathway to resume dosing in non-ambulatory patients, but resumption is uncertain and dependent on FDA analysis.
- ESSENCE Trial: Topline results announced in November 2025 for the ESSENCE confirmatory trial (VYONDYS 53 and AMONDYS 45) did not meet statistical significance on the primary endpoint. The company submitted supplemental NDAs in April 2026, accepted by the FDA in June 2026. There is a risk of regulatory actions, including label changes or market withdrawal.
- LGMD Programs: The FDA placed a clinical hold on LGMD programs (including SRP-9003) in July 2025 following a patient death in a Phase 1 trial. The company is awaiting data from the ELEVIDYS sirolimus study before re-engaging with the FDA on next steps.
- Liquidity: Management believes cash, cash equivalents, and investments ($945.0 million) plus availability under the $600 million Revolving Credit Facility are sufficient to fund operations for at least the next 12 months.
- Leadership Change: Michael Severino, M.D., was appointed CEO effective July 28, 2026, succeeding Douglas Ingram.
Investor Verification Checklist
- ELEVIDYS Demand: Verify the actual uptake of ELEVIDYS in the ambulatory-only population post-label update and the impact on future revenue forecasts.
- ESSENCE Trial Outcome: Monitor FDA decisions regarding the supplemental NDAs for VYONDYS 53 and AMONDYS 45 following the failed primary endpoint in the ESSENCE trial.
- LGMD Clinical Hold: Track the status of the FDA clinical hold on SRP-9003 and the results of the sirolimus study intended to address safety concerns.
- Patent Litigation: Review the final settlement terms for the patent litigations that resulted in the $39.0 million charge and assess remaining exposure.
- Restructuring Savings: Confirm whether the cost reductions from the July 2025 restructuring are sustainable and if they impact the ability to advance the pipeline.